MyFinsight
Home
Blog
About
Contact
Download
Download image
Comprehensive loss
-$121,204K
Unrealized gain (loss) on
marketable securities
$131K
Interest income
$7,447K
Net loss
-$121,335K
Total other income
$2,497K
Interest expense
$4,224K
Change in fair value of
embedded derivatives
-$460K
Other expense, net
-$266K
Loss from operations
-$123,832K
Total operating
expenses
$123,832K
Research and development
$104,885K
General and
administrative
$18,947K
Back
Back
Income Statement
source: myfinsight.com
Acumen Pharmaceuticals, Inc. (ABOS)
Acumen Pharmaceuticals, Inc. (ABOS)